 |
|
Recurrent Thromboembolism After Treatment With Vitamin K Antagonists
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
With respect to our article titled "The Incidence of Recurrent Venous Thromboembolism After Treatment With Vitamin K Antagonists in Relation to Time Since First Event: A Meta-analysis,"1 we want to state the following: There appeared to be a small error in our explanation for observed heterogeneity in the first period after discontinuation of treatment in the group of studies in which patients were treated for 3 months. We assumed that this heterogeneity was due to the relatively high number of patients with cancer included in one study (Kearon et al2 [reference 106 in our study]). However, the authors of that study notified us that in their study no patients with cancer were included.
According to the article of Kearon et al,2 the most likely explanation for the relatively high recurrence rate in the study is the fact that all first events were truly idiopathic. The overall conclusions of our study . . . [Full Text of this Article]
Carlo J. van Dongen, MSc;
Roel Vink, MD;
Barbara A. Hutten, PhD;
Harry R. Büller, MD, PhD
Amsterdam, the Netherlands
Martin H. Prins, MD, PhD
Maastricht, the Netherlands
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
The Incidence of Recurrent Venous Thromboembolism After Treatment With Vitamin K Antagonists in Relation to Time Since First Event: A Meta-analysis
Carlo J. J. van Dongen, Roel Vink, Barbara A. Hutten, Harry R. Büller, and Martin H. Prins
Arch Intern Med. 2003;163(11):1285-1293.
ABSTRACT
| FULL TEXT
|
